Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RELAFEN | Smithkline Beecham | N-019583 DISCN | 1991-12-24 | 2 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
nabumetone | ANDA | 2025-03-26 |
nabumetone 1000 mg nabumetone 500 mg nabumetone 750 mg | ANDA | 2024-01-16 |
relafen | ANDA | 2020-11-25 |
relafen ds | ANDA | 2024-01-08 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Nabumetone |
INN | nabumetone |
Description | Nabumetone is a methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, a cyclooxygenase 2 inhibitor and a prodrug. It is a methoxynaphthalene and a methyl ketone. |
Classification | Small molecule |
Drug class | cannabinol derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc2cc(CCC(C)=O)ccc2c1 |
PDB | — |
CAS-ID | 42924-53-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1070 |
ChEBI ID | 7443 |
PubChem CID | 4409 |
DrugBank | DB00461 |
UNII ID | LW0TIW155Z (ChemIDplus, GSRS) |